DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
复制标题
DOI：
10.1186/s12885-019-5291-3
复制
发表时间：
2019-01-14
期刊：
影响因子：
3.8
通讯作者：
Degerman, Sofie
中科院分区：
文献类型：
--
作者：
Evelonn, Emma Andersson;Landfors, Mattias;Degerman, Sofie
透明细胞肾细胞癌（ccRCC）是肾癌中最常见的亚型，转移后预后较差。高达三分之一的诊断为局部疾病的患者在肾切除术后会发生转移，因此需要新的分子标记来识别肿瘤进展高风险的患者。在本研究中，我们在诊断时进行了全基因组启动子DNA甲基化分析，以确定与进展风险相关的DNA甲基化谱。方法采用Illumina HumanMethylation450K阵列对115例ccRCC患者的诊断组织样本进行分析，发现155,931个启动子相关CpGs的甲基化状态与遗传畸变、基因表达和临床病理参数相关。结果基于全基因组启动子甲基化状态将ccRCC样本分为A/B两类。这些组的样本在肿瘤直径上存在差异(p
BackgroundClear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer and is associated with poor prognosis if metastasized. Up to one third of patients with local disease at diagnosis will develop metastasis after nephrectomy, and there is a need for new molecular markers to identify patients with high risk of tumor progression. In the present study, we performed genome-wide promoter DNA methylation analysis at diagnosis to identify DNA methylation profiles associated with risk for progress.MethodDiagnostic tissue samples from 115 ccRCC patients were analysed by Illumina HumanMethylation450K arrays and methylation status of 155,931 promoter associated CpGs were related to genetic aberrations, gene expression and clinicopathological parameters.ResultsThe ccRCC samples separated into two clusters (cluster A/B) based on genome-wide promoter methylation status. The samples in these clusters differed in tumor diameter (p